Details for New Drug Application (NDA): 017256
✉ Email this page to a colleague
NDA 017256 describes XENON XE 133, which is a drug marketed by Curium, Ge Healthcare, Gen Electric, and Lantheus Medcl, and is included in six NDAs. It is available from two suppliers. Additional details are available on the XENON XE 133 profile page.
The generic ingredient in XENON XE 133 is xenon xe-133. There are twelve drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the xenon xe-133 profile page.
The generic ingredient in XENON XE 133 is xenon xe-133. There are twelve drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the xenon xe-133 profile page.
Summary for 017256
| Tradename: | XENON XE 133 |
| Applicant: | Ge Healthcare |
| Ingredient: | xenon xe-133 |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 1.3-1.7 CI/AMP | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | GAS;INHALATION | Strength | 1 CI/AMP | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
